California fines OptumRx pharmacy; Eli Lilly releases new diabetes drug data

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: The revolving door swings again as Lupin hires an FDA official who oversaw problems at a key plant By Ed Silverman Sarah Silbiger/Getty Images "It's a problem because it can undermine public trust in the agency’s decision making," said Michael Carome of Public Citizen. Read More STAT+: California fines an OptumRx pharmacy for jeopardizing patient health. Is that enough? By Ed Silverman Mark Lennihan/AP This was the second time in recent years the state pharmacy board sought to penalize OptumRx for similar violations committed by the facility. Read More STAT+: With new diabetes drug data, Eli Lilly is taking aim at obesity By Matthew Herper Kristoffer Tripplaar/AP Lilly released new data showing that an injectable diabetes drug it is developing can lead to substantial weight loss in people with obesity. Read More Sponsor content by STAT Events May 3| The journey from lab to patient's bedside Join STAT in Boston to explore the challenges, and the unique opportunities, of the drug development process. We're bringing together speakers from a diverse set of organizations, from Relay Therapeutics to The Progeria Research Foundation, to share their unique perspectives. Get your ticket now to join them. FDA issues plan to ban menthol in cigarettes, cigars By Matthew Perrone — Associated Press Jeff Chiu/AP The FDA said eliminating menthol cigarettes could prevent between 300,000 and 650,000 smoking deaths over 40 years. Read More Thursday, April 28, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser